News
PLRX
1.460
+1.39%
0.020
Weekly Report: what happened at PLRX last week (0407-0411)?
Weekly Report · 6d ago
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Barchart · 04/07 15:05
Weekly Report: what happened at PLRX last week (0331-0404)?
Weekly Report · 04/07 09:03
Pliant Therapeutics: An Activist On Deck
Seeking Alpha · 04/03 16:22
Weekly Report: what happened at PLRX last week (0324-0328)?
Weekly Report · 03/31 09:03
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
NASDAQ · 03/27 13:39
Weekly Report: what happened at PLRX last week (0317-0321)?
Weekly Report · 03/24 09:03
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral
Benzinga · 03/18 15:53
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Benzinga · 03/17 17:39
PLIANT THERAPEUTICS: ANTITUMOR ACTIVITY SEEN WITH CONFIRMED PARTIAL RESPONSES IN 50% OF PATIENTS AT HIGHEST DOSE TESTED TO DATE
Reuters · 03/17 12:09
PLIANT THERAPEUTICS INC: PLN-101095 WAS GENERALLY WELL TOLERATED ACROSS ALL DOSES
Reuters · 03/17 12:09
PLIANT THERAPEUTICS INC: ANNOUNCES INTERIM PHASE 1 DATA FOR PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORS
Reuters · 03/17 12:09
Weekly Report: what happened at PLRX last week (0310-0314)?
Weekly Report · 03/17 09:03
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement In Response To Recent Accumulations Of Its Common Stock
Benzinga · 03/13 11:23
PLIANT THERAPEUTICS- AGREEMENT TO REDUCE LIKELIHOOD ANY ENTITY, PERSON, GROUP ABLE TO GAIN CONTROL OF CO THROUGH OPEN MARKET ACCUMULATION
Reuters · 03/13 11:20
PLIANT THERAPEUTICS ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS AGREEMENT
Reuters · 03/13 11:20
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Barchart · 03/13 10:04
Weekly Report: what happened at PLRX last week (0303-0307)?
Weekly Report · 03/10 09:03
Biotech Alert: Searches spiking for these stocks today
TipRanks · 03/06 17:01
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.